Biological E, Providence Therapeutics tie up for mRNA vaccine, to run trials in India, seek EUA
June 01, 2021
×
Targets 1 billion doses in 2022; Providence to supply 30 million doses from North American capacity
Canadian biotechnology company Providence Therapeutics Holdings Inc and the Hyderabad-based Biological E Ltd have signed up for a licensing and collaboration agreement for Providence’s mRNA vaccine, PTX-Covid19-B.
Providence will provide the technology transfer for Biological E to manufacture mRNA vaccines in India, with a minimum production capacity of 600 million doses in 2022 and a target capacity of 1 billion doses.
The agreement provides for sale of Providence’s 30 million doses of its proprietary mRNA vaccine to Biological E and other end-buyers.
India News: Biopharma player Biological E has joined hands with Canadian player Providence Therapeutics Holdings Inc for licencing the latter’s mRNA vaccine PTX-C
Canada s Providence Therapeutics Holdings Inc and Biological E Ltd on Tuesday announced the execution of a term sheet for sale of up to 30 million doses of the former s proprietary messenger RNA vaccine, PTX-Covid19-B, to Biological E and other .